Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733611 · ClinicalTrials.gov registry record · Phase 2
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
A Phase 2 study, sponsored by Replimune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT05733611 is a Phase 2 study that was terminated before completion, run by Replimune. The registered enrollment target is 5 participants.
The verdict
NCT05733611, a Phase 2 study, was terminated before completion, sponsored by Replimune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
Interventions
- BIOLOGICAL RP2
- BIOLOGICAL atezolizumab
- BIOLOGICAL RP3
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2025-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05733611
The ClinicalTrials.gov registry entry for NCT05733611 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Replimune, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which RP2 is the first listed.
NCT05733611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05733611 about?
NCT05733611 is a clinical study titled "RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC". This is an open-label, Phase 2 clinical trial evaluating therapy with an oncolytic immunotherapy (RP2 or RP3) in combination with atezolizumab and bevacizumab in patients with advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma.
What is the current status of trial NCT05733611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2023-06-29. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT05733611?
The interventions under investigation include: RP2 (BIOLOGICAL), atezolizumab (BIOLOGICAL), RP3 (BIOLOGICAL), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05733611?
This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.